| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/20/2008 | WO2007078615A3 Methods and compositions for treatment of cancer |
| 03/20/2008 | WO2007075318A3 Agents that reduce apoe-induced impairment of mitochondria and methods of use thereof |
| 03/20/2008 | WO2007065021A3 A predictive tool for hyaluronidase treatment success |
| 03/20/2008 | WO2007053502A3 Mutations and polymorphisms of hdac5 |
| 03/20/2008 | WO2007016791A8 Reducing post-operative adhesion formation with intraperitoneal glutamine |
| 03/20/2008 | WO2006120226A8 Stabilizer molecule-depleted albumin solution |
| 03/20/2008 | WO2005105840A3 Cd40 variants and uses thereof |
| 03/20/2008 | WO2004111075A3 Alternative reading frame polypeptides for treatment |
| 03/20/2008 | WO2001030965A3 Methods of in vivo gene transfer using a sleeping beauty transposon system |
| 03/20/2008 | WO2000074709A3 Modified biodegradable polyester microspheres for stabilizing and improving the release profile of drugs encapsulated within the microspheres |
| 03/20/2008 | US20080071069 For delivering DNA/RNA into cells |
| 03/20/2008 | US20080071066 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 03/20/2008 | US20080071065 Fibroblast Growth Factor-Like Polypeptides |
| 03/20/2008 | US20080070953 Inhibitors of interleukin-1 beta converting enzyme |
| 03/20/2008 | US20080070858 Administering a natriuretic hormone peptide (NHP), or a nucleic acid sequence encoding NHP; respiratory system disorders |
| 03/20/2008 | US20080070855 Preventing post-operative neovascularization in ophthalmic tissue; administering bevacizumab |
| 03/20/2008 | US20080070854 Conserved Hbv and Hcv Sequences Useful for Gene Silencing |
| 03/20/2008 | US20080070853 Peptides Selectively Lethal to Malignant and Transformed Mammalian Cells |
| 03/20/2008 | US20080070844 Method for treating wounds to promote healing |
| 03/20/2008 | US20080070843 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
| 03/20/2008 | US20080070842 Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| 03/20/2008 | US20080070841 Treating or preventing cardiovascular abnormal conditions related to thrombosis or embolism by administering serine proteinase inhibitor-1 (SERP-1) and a carrier; kits |
| 03/20/2008 | US20080070840 Polypeptides or peptides modified to include at least one antibody Fc region and, optionally, one or more water soluble polymers; have ability to stimulate in vivo and in vitro production of platelets, and/or megakaryocytopoietic activity, i.e., the ability to stimulate production of platelet precursors |
| 03/20/2008 | US20080070839 Composition and method for treating cancer |
| 03/20/2008 | US20080070838 Growth Factor Treatment for Asthma |
| 03/20/2008 | US20080070837 Variants of human bone morphogenetic proteins and other cysteine knot cytokine proteins with improved properties, including increased expression yield, expression in absence of a pro-domain, increased solubility, increased specific activity, altered receptor, co-receptor, inhibitor specificity |
| 03/20/2008 | US20080070836 Zinc transporter LIV1 can be used as an epithelial-mesenchymal transition (EMT) regulatory agent; further, because EMT is involved in cancer progression, LIV1 antisense nucleotides and the like may be used as pharmaceuticals for treating cancer |
| 03/20/2008 | US20080070835 Hla-Dr-Binding Antigen Peptide Derived From Wt1 |
| 03/20/2008 | US20080070834 Cyclosporin Compositions |
| 03/20/2008 | US20080070833 Lactoferrin in the reduction of pain |
| 03/20/2008 | US20080070832 Subjecting a liquid containing FSH to a dye affinity chromatography, a hydrophobic interaction chromatography, and a reverse phase chromatography, which may be performed in any order; avoids the use of cost-intensive immunoaffinity chromatography steps |
| 03/20/2008 | US20080070831 Endothelial growth factor; isolated polypeptide; stimulates cell proliferation, neovascularization, vascular system permeability; uses thereof in medical and diagnostic applications |
| 03/20/2008 | US20080070830 Homing of cells to myocardium |
| 03/20/2008 | US20080070828 Ace-Inhibitory Whey Hydrolysates |
| 03/20/2008 | US20080070827 Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg coa reductase, and increase ldl receptor and sp1 expression in a mammal |
| 03/20/2008 | US20080070300 Human chemotactic cytokine |
| 03/20/2008 | US20080070279 Group of Synthetic Antimicrobal Peptides |
| 03/20/2008 | US20080070278 Immunoglobulin fusion comprising clostridial light chain for use in controlling interaction of particular cell types with their external environment; drug targeting and delivery |
| 03/20/2008 | US20080070275 Factor VIII: Remodeling and glycoconjugation of factor VIII |
| 03/20/2008 | US20080070267 changing the pattern of Ca2+ spike activity of the neuron; treating psychological disorder using electrical or chemical stimulants, or antagonist; altering neurotransmitter expression; autism, anxiety disorder, post-traumatic stress disorder, depression, bipolar disorder and schizophrenia |
| 03/20/2008 | US20080070259 Using presence or absence of mutation in metalloenzyme polynucleotides as diagnostic indicator of cardiovascular and neurodegenerative disorders |
| 03/20/2008 | US20080070258 Polyamide nucleic acid derivatives and agents, and processes for preparing them |
| 03/20/2008 | US20080070248 Using allelic variation to predict response of individuals to growth hormone receptor (GHR) modulators; treating obesity and acromegaly |
| 03/20/2008 | US20080069869 Formulations and methods for modulating satiety |
| 03/20/2008 | US20080069865 Congestive heart failure; antiischemic agents; administering calcitonin gene related peptide in thermoplastic biocompatible polymer; controlled release or maintenance therapy |
| 03/20/2008 | US20080069862 Mixture of collagen, chondroitin sulfate, glucosamine sulfate with metal compounds and herbs |
| 03/20/2008 | US20080069859 Method for treating neovascularization and intravitreal implants |
| 03/20/2008 | US20080069855 Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss |
| 03/20/2008 | US20080069849 Genetic engineered polypeptide; bactericides, viricides, fungicides, parasiticides |
| 03/20/2008 | US20080069846 Gene coding, gene expression, purification; used as detergents, cosmetics, leather processing, softening for food, meats, animal feeds |
| 03/20/2008 | US20080069834 Moderation of gene expression; administering antioxidant to mammals; reduce oxidation stresses |
| 03/20/2008 | US20080069830 Isolation Dna; nucleotide sequences; genetic engineering |
| 03/20/2008 | US20080069829 Ability to bind to antibodies; diagnosis of allergies |
| 03/20/2008 | US20080069826 Novel Genes Associated with the Maintenance of Differentiation of Smooth Muscle Cells |
| 03/20/2008 | US20080069823 Attenuation of Reperfusion Injury |
| 03/20/2008 | US20080069814 High dosage administered without inducing severe symptomatic hypercalcemia |
| 03/20/2008 | US20080069812 Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents |
| 03/20/2008 | US20080069810 Pharmaceutical Composition Comprising Factor VII Polypeptides and TAFI Polypeptides |
| 03/20/2008 | US20080069809 Administering ingenol angelate to treat cancer cells having high protein kinase C (PKC) activity; myeloid leukiemia |
| 03/20/2008 | US20080069808 Ec Sod and Cell Transducing Ec Sod and Use Thereof |
| 03/20/2008 | US20080069806 Method of screening for substances useful for transdifferentiation of microglia into neurons |
| 03/20/2008 | US20080069803 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions vectors |
| 03/20/2008 | US20080069801 Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications |
| 03/20/2008 | US20080069800 System for High Production of Natural and Personalized Interferons |
| 03/20/2008 | US20080069799 Use of il-22 for the treatment of conditions of metabolic disorders |
| 03/20/2008 | US20080069798 Hyperlipidemia, obesity, hyperinsulinemia and diabetes; gene therapy |
| 03/20/2008 | US20080069797 Rapamycin and il-10 for the treatment of immune diseases |
| 03/20/2008 | US20080069796 Low Dose Treatment with an Interleukin-11 Analog |
| 03/20/2008 | US20080069795 Depleting T cells in the patient prior to a administration of a platinum-containing compound |
| 03/20/2008 | US20080069791 Administering composition of a polynucleotide, a polypeptide encoded by the nucleic acid and a compound which binds to an antibody which recognizes the polypeptide or binds to an IL- 15 receptor alpha chain; using a transgenic animal comprising an IL-15 polynucleotide |
| 03/20/2008 | US20080069774 Targeting ligand specifically binding to an extracellular component of a cellular system, masking the extracellular component from interacting with a component of the cellular system; thrombotic occlusion and loss of vessel patency at the site of the vascular intervention |
| 03/20/2008 | US20080069772 Treatment of transformed or infected biological cells |
| 03/20/2008 | US20080069770 Monoclonal antibodies; used to modulate the immune system; no modulation of the totality of the T-cell population but only of the sub-assembly of T-cells expressing the beta sub-family specific to the T-cell receptors; used for organ transplant rejection |
| 03/20/2008 | US20080068245 A-d converter and a-d convert method |
| 03/20/2008 | DE10080167B4 Medikament zur Hemmung der Expression eines vorgegebenen Gens Medicament for inhibiting the expression of a given gene |
| 03/20/2008 | CA2664066A1 Products and methods using soy peptides to lower total and ldl cholesterol levels |
| 03/20/2008 | CA2663571A1 Methods for treating cancer |
| 03/20/2008 | CA2663417A1 Methods and compositions for sealing and adhering biological tissues and medical uses thereof |
| 03/20/2008 | CA2663416A1 High pressure treatment of proteins for reduced immunogenicity |
| 03/20/2008 | CA2663352A1 Albumin fusion proteins |
| 03/20/2008 | CA2663293A1 Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases |
| 03/20/2008 | CA2663273A1 Methods and compositions for promoting organ development |
| 03/20/2008 | CA2663188A1 Modifications of cupredoxin derived peptides and methods of use thereof |
| 03/20/2008 | CA2663069A1 Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| 03/20/2008 | CA2662981A1 Targeted polymeric prodrugs containing multifunctional linkers |
| 03/20/2008 | CA2662799A1 Method for producing insulin in the form of an oral preparation |
| 03/20/2008 | CA2662622A1 Methods for administering long-lasting hypoglycemic agents |
| 03/20/2008 | CA2662609A1 Modulation of regulatory t cells by human il-18 |
| 03/20/2008 | CA2662520A1 Polymeric conjugates containing positively-charged moieties |
| 03/20/2008 | CA2662432A1 Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |
| 03/20/2008 | CA2661892A1 Gel type enteral nutrient |
| 03/20/2008 | CA2659070A1 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
| 03/19/2008 | EP1900823A2 Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents |
| 03/19/2008 | EP1900818A2 Neisserial antigens |
| 03/19/2008 | EP1900816A2 GL50 molecules and uses therefor |
| 03/19/2008 | EP1900813A1 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
| 03/19/2008 | EP1900380A1 Pharmaceutical composition for vascular occlusive disease |
| 03/19/2008 | EP1900376A2 Synergistic inhibition of HIV-1 fusion and attachment, compsitions and antobodies thereto |
| 03/19/2008 | EP1900375A1 Calreticulin for its use as a medication for the treatment of cancer in a mammal |
| 03/19/2008 | EP1900374A1 Angiogenetic agent containing adrenomedulin as the active ingredient |